Can odomzo be used for advanced bcc?

What makes Odomzo a treatment for advanced BCC?

Odomzo contains sonidegib, a hedgehog pathway inhibitor that works by blocking the signaling responsible for uncontrolled cell growth in basal cell carcinoma. It is approved for adults with locally advanced BCC that recurs after surgery or radiation, or for patients who cannot have those treatments. It is also approved for metastatic BCC.

How does Odomzo compare with Erivedge?

Erivedge is the earlier hedgehog pathway inhibitor that contains vismodegib. Both drugs target the hedgehog pathway, but Odomzo uses a different active ingredient. The two drugs show similar rates of objective response in clinical studies. In practice, physicians often switch patients between them if one causes side effects or loses effectiveness.

What are the typical side effects patients report?

Common side effects include muscle spasms, hair loss, altered taste, weight loss, and fatigue. Higher doses or lang<|eos|>